University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Human iPSC-derived chimeric antigen receptor-expressing macrophages for cancer treatment |
$222,200 |
City of Hope, Beckman Research Institute |
Karen Aboody |
Therapeutic Translational Research Projects |
Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer |
$2,873,262 |
University of California, Los Angeles |
Yvonne Chen |
Therapeutic Translational Research Projects |
BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma |
$3,176,805 |
City of Hope, Beckman Research Institute |
Saul Priceman |
Clinical Trial Stage Projects |
A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$9,015,149 |
University of California, Los Angeles |
Theodore Nowicki |
Clinical Trial Stage Projects |
Genetic Modification of Stem Cells and T cells to Activate the Immune System to Target Solid Tumors |
$4,693,839 |
Angiocrine Bioscience, Inc. |
Edward Kavalerchik |
Clinical Trial Stage Projects |
AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205 |
$6,192,579 |
Stanford University |
Philip Beachy |
Quest - Discovery Stage Research Projects |
Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer |
$1,265,436 |
University of California, San Francisco |
Karin Gaensler |
Therapeutic Translational Research Projects |
Developing engineered autologous leukemia vaccines to target residual leukemic stem cells |
$4,171,728 |
Poseida Therapeutics, Inc. |
Devon Shedlock |
Late Stage Preclinical Projects |
Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer |
$3,992,090 |
University of California, San Francisco |
Hideho Okada |
Quest - Discovery Stage Research Projects |
Non-viral reprogramming of the endogenous TCRα locus to direct stem memory T cells against shared neoantigens in malignant gliomas |
$900,000 |
City of Hope, Beckman Research Institute |
Saul Priceman |
Quest - Discovery Stage Research Projects |
Chimeric Antigen Receptor-Engineered Stem/Memory T Cells for the Treatment of Recurrent Ovarian Cancer |
$1,381,104 |
University of California, Los Angeles |
Lili Yang |
Quest - Discovery Stage Research Projects |
Preclinical Development of An HSC-Engineered Off-The-Shelf iNKT Cell Therapy for Cancer |
$1,404,000 |
City of Hope, Beckman Research Institute |
John Zaia |
Late Stage Preclinical Projects |
Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients |
$3,684,259 |
University of California, Los Angeles |
Steven Dubinett |
Clinical Trial Stage Projects |
A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$10,955,315 |
Stanford University |
Crystal Mackall |
Clinical Trial Stage Projects |
Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies |
$11,034,982 |
Fate Therapeutics, Inc. |
Bob Valamehr |
Late Stage Preclinical Projects |
IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell |
$4,000,000 |
University of California, San Diego |
Tannishtha Reya |
Quest - Discovery Stage Research Projects |
Targeting Cancer Stem Cells in Hematologic Malignancies |
$1,960,560 |
University of California, San Diego |
Catriona Jamieson |
Therapeutic Translational Research Projects |
A Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia |
$2,511,767 |
University of California, San Diego |
Dan Kaufman |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment |
$4,698,821 |
Human BioMolecular Research Institute |
John Cashman |
Inception - Discovery Stage Research Projects |
Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication |
$303,785 |
Loma Linda University |
Julia Unternaehrer-Hamm |
Inception - Discovery Stage Research Projects |
Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer |
$172,870 |
Loma Linda University |
David Baylink |
Inception - Discovery Stage Research Projects |
Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1-α-hydroxylase for Acute Myeloid Leukemia Therapy |
$178,967 |
Children's Hospital of Los Angeles |
Michael Pulsipher |
Clinical Trial Stage Projects |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) |
$4,825,587 |
Poseida Therapeutics, Inc. |
Matthew Spear |
Clinical Trial Stage Projects |
Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma |
$19,813,407 |
Nohla Therapeutics Inc |
Colleen Delaney |
Clinical Trial Stage Projects |
A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML |
$4,310,000 |
City of Hope, Beckman Research Institute |
Christine Brown |
Clinical Trial Stage Projects |
Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma |
$12,753,854 |
Angiocrine Bioscience, Inc. |
Edward Kavalerchik |
Clinical Trial Stage Projects |
AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 |
$5,000,000 |
University of California, San Diego |
Thomas Kipps |
Clinical Trial Stage Projects |
A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers |
$18,292,674 |
University of California, San Diego |
Ezra Cohen |
Therapeutic Translational Research Projects |
Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies |
$5,795,584 |
University of California, Los Angeles |
Gay Crooks |
Quest - Discovery Stage Research Projects |
Platform Technology for Pluripotent Stem Cell-Derived T cell Immunotherapy |
$965,636 |
Cellerant Therapeutics, Inc. |
Swapna Panuganti |
Late Stage Preclinical Projects |
Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia |
$6,863,755 |
City of Hope, Beckman Research Institute |
Markus Müschen |
Quest - Discovery Stage Research Projects |
Lgr5-mediated self-renewal in B cell selection and leukemia-initiation |
$2,186,520 |
University of California, San Diego |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$279,977 |
City of Hope, Beckman Research Institute |
Yuan Chen |
Quest - Discovery Stage Research Projects |
A Novel Approach to Eradicate Cancer Stem Cells |
$1,539,935 |
University of California, San Diego |
Dan Kaufman |
Quest - Discovery Stage Research Projects |
Targeted off-the-shelf immunotherapy to treat refractory cancers |
$1,936,936 |
University of California, Los Angeles |
John Chute |
Quest - Discovery Stage Research Projects |
Protein tyrosine phosphatase - sigma inhibitors for hematopoietic regeneration |
$2,116,708 |
Stanford University |
Hiromitsu Nakauchi |
Quest - Discovery Stage Research Projects |
Novel Rejuvenated T Cell Immunotherapy for Lung Cancer |
$1,968,456 |
Stanford University |
Albert Wong |
Therapeutic Translational Research Projects |
2nd Generation Vaccine for the Treatment of Glioblastoma |
$2,929,889 |
Stanford University |
Philip Beachy |
Inception - Discovery Stage Research Projects |
Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells |
$210,906 |
University of California, Berkeley |
Jacob Corn |
Inception - Discovery Stage Research Projects |
Genome editing for causation and reversion of MPN-associated mutations in human hematopoietic stem cells |
$235,800 |
University of California, Los Angeles |
Owen Witte |
Inception - Discovery Stage Research Projects |
Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
University of California, Los Angeles |
Lili Yang |
Therapeutic Translational Research Projects |
Stem Cell-Based iNKT Cell Therapy for Cancer |
$6,956,775 |
Angiocrine Bioscience, Inc. |
Paul Finnegan |
Late Stage Preclinical Projects |
Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy |
$3,797,117 |
ImmunoCellular Therapeutics |
Anthony Gringeri |
Clinical Trial Stage Projects |
A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy |
$5,391,016 |
University of California, Davis |
Mehrdad Abedi |
Clinical Trial Stage Projects |
Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients |
$8,414,265 |
Caladrius Biosciences |
Robert Dillman |
Clinical Trial Stage Projects |
Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. |
$3,000,000 |
University of California, Los Angeles |
John Chute |
Research Leadership |
Niche-Focused Research: Discovery & Development of Hematopoietic Regenerative Factors |
$4,645,297 |
University of California, San Diego |
David Cheresh |
Basic Biology V |
CD61-driven stemness program in epithelial cancer |
$1,161,000 |
University of California, San Diego |
Thomas Kipps |
Disease Team Therapy Development III |
Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) |
$4,179,598 |
Stanford University |
Irving Weissman |
Disease Team Therapy Development III |
Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors |
$6,505,568 |
University of California, Los Angeles |
Dennis Slamon |
Disease Team Therapy Development III |
A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors |
$5,683,693 |
University of California, Los Angeles |
Robert Reiter |
Early Translational IV |
Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells |
$4,075,668 |
University of California, San Francisco |
Ann Zovein |
New Faculty Physician Scientist |
Human endothelial reprogramming for hematopoietic stem cell therapy. |
$2,197,683 |
Stanford University |
Michelle Monje |
New Faculty Physician Scientist |
White matter neuroregeneration after chemotherapy: stem cell therapy for “chemobrain” |
$2,800,526 |
Stanford University |
Michael Cleary |
Basic Biology IV |
Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells |
$1,244,455 |
University of California, Los Angeles |
Owen Witte |
Basic Biology IV |
Trop2 dependent and independent mechanisms of self-renewal in human cancer stem cells |
$1,254,960 |
University of California, Los Angeles |
Antoni Ribas |
Disease Team Therapy Development - Research |
Genetic Re-programming of Stem Cells to Fight Cancer |
$14,144,221 |
City of Hope, Beckman Research Institute |
Stephen Forman |
Early Translational III |
Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells |
$5,215,447 |
University of California, Los Angeles |
Antoni Ribas |
Disease Team Therapy Planning I |
Genetic Re-programming of Stem Cells to Fight Cancer |
$97,785 |
Stanford University |
Albert Wong |
Disease Team Therapy Planning I |
Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma |
$109,750 |
OncoMed Pharmaceuticals, Inc. |
Timothy Hoey |
Disease Team Therapy Planning I |
Anti-Notch1, OMP-52M51: A New Cancer Therapeutic to Reduce CSC Frequency |
$65,120 |
University of California, Davis |
Mehrdad Abedi |
Disease Team Therapy Planning I |
Stem Cell Gene Therapy for HIV in AIDS Lymphoma Patients |
$66,880 |
Gordon Research Conferences |
Catriona Jamieson |
Conference |
2011 Gordon Conference on Stem Cells and Cancer |
$40,000 |
University of California, Los Angeles |
Noriyuki Kasahara |
Early Translational II |
Stem cell-based carriers for RCR vector delivery to glioblastoma |
$3,340,625 |
University of California, San Diego |
Catriona Jamieson |
Early Translational II |
Preclinical development of a pan Bcl2 inhibitor for cancer stem cell directed therapy |
$3,103,041 |
University of California, San Francisco |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$2,756,536 |
Children's Hospital of Los Angeles |
Markus Muschen |
Early Translational II |
Dual targeting of tyrosine kinase and BCL6 signaling for leukemia stem cell eradication |
$850,769 |
Sanford Burnham Prebys Medical Discovery Institute |
Robert Wechsler-Reya |
Research Leadership |
The role of neural stem cells in cerebellar development, regeneration and tumorigenesis |
$5,226,049 |
University of California, San Diego |
Dennis Carson |
Disease Team Research I |
Development of Highly Active Anti-Leukemia Stem Cell Therapy (HALT) |
$19,999,826 |
City of Hope, Beckman Research Institute |
Karen Aboody |
Disease Team Research I |
Stem Cell-mediated Therapy for High-grade Glioma: Toward Phase I-II Clinical Trials |
$17,890,623 |
University of California, Los Angeles |
Dennis Slamon |
Disease Team Research I |
Therapeutic Opportunities To Target Tumor Initiating Cells in Solid Tumors |
$19,979,660 |
Stanford University |
Irving Weissman |
Disease Team Research I |
Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
University of California, San Francisco |
Mitchel Berger |
Disease Team Research I |
Stem Cell-Mediated Oncocidal Gene Therapy of Glioblastoma (GBM) |
$6,214,914 |
University of California, Los Angeles |
Antoni Ribas |
New Faculty II |
Stem Cells for Immune System Regeneration to Fight Cancer |
$3,072,000 |
University of California, Los Angeles |
Brigitte Gomperts |
New Faculty II |
Stem Cells in Lung Cancer |
$2,381,572 |
University of California, San Diego |
Catriona Jamieson |
New Faculty II |
Derivation and Characterization of Myeloproliferative Disorder Stem Cells from Human ES Cells |
$3,065,572 |
University of California, San Francisco |
Emmanuelle Passegue |
New Faculty II |
Mechanisms Underlying the Responses of Normal and Cancer Stem Cells to Environmental and Therapeutic Insults |
$2,124,488 |
University of California, Los Angeles |
Zack Jerome |
New Cell Lines |
Generation of clinical grade human iPS cells |
$1,341,000 |
City of Hope, Beckman Research Institute |
Michael Barish |
Disease Team Planning |
Genetically-modified neural stem cells for treatment of high-grade glioma |
$55,000 |
University of California, Los Angeles |
Siavash Kurdistani |
New Faculty I |
Epigenetics in cancer stem cell initiation and clinical outcome prediction |
$3,063,450 |
University of California, Los Angeles |
Hanna Mikkola |
New Faculty I |
Mechanisms of Hematopoietic stem cell Specification and Self-Renewal |
$2,286,900 |
University of California, Davis |
Chong-Xian Pan |
New Faculty I |
Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells |
$2,386,409 |
University of California, San Diego |
Yang Xu |
Comprehensive Grant |
Mechanisms to maintain the self-renewal and genetic stability of human embryonic stem cells |
$2,467,200 |
University of Southern California |
Peter Laird |
SEED Grant |
Screening for Oncogenic Epigenetic Alterations in Human ES Cells |
$647,431 |
Gladstone Institutes, J. David |
Warner Greene |
SEED Grant |
The APOBEC3 Gene Family as Guardians of Genome Stability in Human Embryonic Stem Cells |
$717,363 |
University of California, Irvine |
Charles Limoli |
SEED Grant |
Using human embryonic stem cells to treat radiation-induced stem cell loss: Benefits vs cancer risk |
$593,242 |
Children's Hospital of Los Angeles |
Elizabeth Lawlor |
SEED Grant |
hESC as tools to investigate the neural crest origin of Ewing's sarcoma |
$595,576 |
Stanford University |
Julien Sage |
SEED Grant |
Functions of RB family proteins in human embryonic stem cells |
$498,609 |
University of California, Los Angeles |
Zoran Galic |
SEED Grant |
Genetic Enhancement of the Immune Response to Melanoma via hESC-derived T cells |
$616,800 |
City of Hope, Beckman Research Institute |
Timothy O'Connor |
SEED Grant |
Sources of Genetic Instability in Human Embryonic Stem Cells. |
$327,311 |
University of California, San Francisco |
Thea Tlsty |
SEED Grant |
Role of the tumor suppressor gene, p16INK4a, in regulating stem cell phenotypes in embryonic stem cells and human epithelial cells. |
$614,784 |
University of California, San Diego |
Catriona Jamieson |
SEED Grant |
Derivation and Characterization of Cancer Stem Cells from Human ES Cells |
$616,305 |